Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The agilon health, inc. (AGL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. agilon health describes itself as a trusted partner empowering physicians to transition senior patients to a value-based Total Care Model, and its filings offer detail on how this business is structured and governed.
Investors can review current and historical reports such as Form 8-K filings, where agilon health has reported items including quarterly financial results, leadership transitions, amendments to by-laws, and notices related to New York Stock Exchange continued listing standards. These documents give additional context to the company’s announcements about its operations, value-based care arrangements, and corporate governance.
Through its periodic reports referenced in these filings, agilon health discusses topics such as risk factors associated with its value-based care model, relationships with payors and physician partners, and its reliance on medical services as a source of revenue. The filings may also describe compensation and employment arrangements for key executives, as reflected in agreements disclosed in Form 8-K exhibits.
On Stock Titan, users can combine direct access to agilon health’s SEC documents with AI-powered tools that summarize key points and highlight important sections. This can help readers more quickly understand complex disclosures related to financial performance, listing status, executive arrangements, and other matters that affect agilon health’s value-based healthcare business.
Agilon Health director John William Wulf increased his stake in the company. On 11/12/2025, he purchased 81,000 shares of agilon health, inc. common stock in open-market transactions at a weighted average price of $0.6289 per share, with individual trades ranging from $0.6251 to $0.6321.
Following this purchase, he directly beneficially owns 365,857 shares of common stock, which include restricted stock units.
The Vanguard Group filed an amended Schedule 13G/A reporting passive ownership of agilon health Inc. common stock. As of 12/31/2025, Vanguard reported beneficial ownership of 18,321,808 shares, representing 4.41% of the outstanding common stock.
Vanguard reported shared voting power over 2,261,393 shares and shared dispositive power over 18,321,808 shares, with no sole voting or dispositive power. Vanguard states the shares are held in the ordinary course of business and not with the purpose of influencing control of agilon health.
The filing notes that on January 12, 2026, Vanguard underwent an internal realignment and no longer performs portfolio management or proxy voting. Certain Vanguard subsidiaries or divisions pursuing the same investment strategies are expected to report beneficial ownership separately on a disaggregated basis.
agilon health, inc. reported an insider equity award to its Chief Financial Officer, Jeffrey A. Schwaneke. On January 10, 2026, he received 600,000 shares of common stock in the form of restricted stock units at a stated price of $0 per share. These restricted stock units vest in three equal installments on each anniversary of January 10, 2026, providing a three-year vesting schedule. Following this grant, Schwaneke beneficially owns 1,675,122 shares of agilon health common stock, which includes restricted stock units, all held directly.
agilon health, inc. reported that it entered into an Amended and Restated Employment Agreement with its Chief Financial Officer and Executive Vice President, Jeffrey Schwaneke, effective January 1, 2026. The updated agreement is described as substantially the same as his prior agreement, with key changes focused on equity compensation and severance terms.
Under the new agreement, Mr. Schwaneke will receive a one-time grant of 600,000 restricted stock units (RSUs) scheduled to vest annually over three years. If he is employed when agilon grants annual equity awards for fiscal year 2026 to its executive officers, he is to receive awards with an aggregate grant-date fair value of $3,750,000, with terms consistent with other executives. He will also be eligible for annual equity awards for fiscal year 2027 in the ordinary course.
If his employment is terminated by the company without cause (and not due to death or disability) before 18 months after January 1, 2026, the agreement provides cash severance equal to 12 months of base salary and target annual bonus, plus continued vesting of equity awards granted under this agreement as if his employment had not ended, subject to a release of claims. The same continued vesting treatment applies if he voluntarily resigns more than 18 months after January 1, 2026.
agilon health (AGL): Schedule 13G/A — passive ownership update. North Peak Capital Management, LLC and affiliated entities filed Amendment No. 1 reporting beneficial ownership of 39,411,957 shares of AGL, representing 9.5% of the class, based on 414,581,604 shares outstanding as of October 30, 2025.
Affiliates including North Peak Capital GP, LLC and individuals Michael K. Kahan and Jeremy S. Kahan each report 31,971,936 shares (7.7%). North Peak Capital Management lists shared voting power: 31,971,936 and sole dispositive power: 7,440,021, with additional shared dispositive power of 31,971,936. Reported holdings include, for example, North Peak Capital Partners II, LP: 18,382,413 shares and North Peak Capital Alpha Fund, LP: 9,840,951 shares.
The filing certifies the securities were not acquired and are not held for the purpose of changing or influencing control, consistent with a passive 13G status. The stated event date is September 30, 2025.
agilon health (AGL) reported it received a notice from the NYSE on November 5, 2025 stating the company is no longer in compliance with Section 802.01C because its common stock’s average closing price was below $1.00 over a consecutive 30 trading‑day period ended November 4, 2025.
The company has a six‑month cure period to regain compliance if, on the last trading day of any calendar month (or the last day of the cure period), the closing price is at least $1.00 and the 30‑day average is at least $1.00. AGL plans to notify the NYSE by November 19, 2025 that it intends to remain listed and anticipates pursuing a reverse stock split, subject to stockholder approval. The company expects to seek that approval at its 2026 annual general meeting. Under NYSE rules, if stockholders approve an action like a reverse split no later than the next annual meeting, the price deficiency is deemed cured if, after implementation, the share price promptly exceeds $1.00 and remains above that level for at least 30 trading days.
The company issued a related press release on November 7, 2025.
FMR LLC filed an amended Schedule 13G (Amendment No. 1) reporting beneficial ownership of 15,377,531.37 shares of agilon health, inc. (AGL) common stock, representing 3.7% of the class as of 09/30/2025.
FMR reports sole voting power over 15,374,685.00 shares and sole dispositive power over 15,377,531.37 shares, with no shared voting or dispositive power. Abigail P. Johnson is also a reporting person, with sole dispositive power over 15,377,531.37 shares and no voting power.
The filing indicates ownership of 5 percent or less of the class. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. One or more other persons may have rights to dividends or sale proceeds, and none exceeds five percent.
agilon health (AGL) reported Q3 2025 results showing continued top-line scale with pressure on medical costs. Total revenue was $1.4 billion, while medical services expense of $1.49 billion drove a gross loss of $67.6 million. Net loss was $110.2 million (basic and diluted EPS $(0.27)).
Medicare Advantage membership was 502,800, down 4% year over year. Adjusted EBITDA loss was $91 million. Cash and cash equivalents were $171.7 million with marketable securities of $139.2 million as of September 30, 2025. Medical claims and related payables rose to $1,059.4 million, reflecting ongoing utilization and IBNR estimates. Shares outstanding were 414,570,000 at quarter end and 414,581,604 at October 30, 2025.
On liquidity, the company had $35.0 million outstanding under its term loan and $83.2 million of standby letters of credit, leaving $16.8 million available on the revolving facility, which matures on February 18, 2026. The effective interest rate on the term loan was 8.272%.
agilon health, inc. furnished an update on its latest performance. On November 4, 2025, the company provided a press release detailing financial results for the three and nine months ended September 30, 2025, and shared an investor presentation.
The materials were furnished, not filed, under Items 2.02 and 7.01, which limits their use under certain Exchange Act provisions. The press release appears as Exhibit 99.1 and the investor presentation as Exhibit 99.2.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 24,292,603 shares of agilon health (AGL) common stock, representing 5.86% of the class as of 09/30/2025.
The filing lists 0 shares with sole voting power and 2,076,130 with shared voting power. It reports 21,890,675 shares with sole dispositive power and 2,401,928 with shared dispositive power. Vanguard states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.